Vitrafy Life Sciences Raising $30m to Scale Guardion Production and US Expansion

Vitrafy Life Sciences (ASX: VFY) has secured firm commitments for a $30 million institutional placement to expand manufacturing of its Guardion cryopreservation devices and accelerate its US operations.

The raising follows recent progress in the US blood market, where the company is positioning its technology against urgent supply constraints and an approaching replacement cycle for legacy frozen-blood infrastructure.

Vitrafy will issue approximately 11.54 million new shares at $2.60 each, with the placement supported by new and existing institutional and sophisticated investors.

The offer price represents a discount of 31.6% to the last closing price of A$3.80 on 9 June 2026 and an 8.8% discount to the 15-day volume weighted average price of A$2.851 up to and including the same date.

Eligible shareholders in Australia and New Zealand will also be offered a non-underwritten share purchase plan (SPP) targeting up to a further $2m at the same issue price.

Scaling Guardion Supply

Vitrafy intends to allocate $15m of the placement proceeds to building its Guardion device fleet, with $8m directed to US sales and operations, $5.2m to working capital and $1.8m to raising costs.

Guardion forms the hardware component of an integrated cryopreservation platform that combines controlled-rate freezing, LifeChain cloud software, point-of-care thawing equipment, and recurring-use consumables.

The company is scaling production as it prepares for anticipated demand from the US blood sector, where existing red blood cell processing equipment and glycerol-based cryoprotectants are due to be phased out by the end of 2027.

The company’s recently announced Vitalant partnership will begin with two Vitrafy service packages at its research institute as the parties pursue next-generation red blood cell solutions for rare blood programs, stockpiling and emergency preparedness.

US Blood Opportunity

The US blood network faces chronic platelet shortages, short shelf lives, and the absence of an approved replacement for ageing frozen red blood cell infrastructure.

Approximately 2.6 million platelet units are collected annually in the US, while a shelf life of less than seven days contributes to an estimated US$280m in yearly wastage.

Vitrafy’s platelet work has produced 94.4% post-thaw recovery in Phase I and Phase II US Army studies, exceeding cited European and US benchmarks.

The company is targeting Guardion medical device registration in the first half of the 2027 financial year as it continues engagement with the US Food and Drug Administration on pathways for red blood cell applications.

Broader Commercial Platform

Vitrafy has designed its managed-service model around recurring monthly fees for hardware, software, and support, supplemented by consumable revenue linked to the number of cryopreservation cycles performed.

Its animal reproduction business provides an existing commercial pathway, including a revenue-generating agreement with IMV Technologies to develop a global offering across aquaculture, bovine, and potentially other species.

The company is also pursuing cell and gene therapy applications, where preserving high-value biological materials with minimal loss of viability could support manufacturers and blood centres supplying raw materials.

Proceeds from the raising will allow Vitrafy to pursue these opportunities while prioritising the near-term manufacturing and operational requirements attached to its US blood-market strategy.

Commercialisation Momentum

Managing director and chief executive officer Brent Owens said the funding would support the next stage of Vitrafy’s commercial expansion.

“With recent commercial milestones being achieved in the US blood market, we are more increasingly confident about the growth opportunities for the company,” he said.

“This capital enables us to scale Guardion manufacturing to meet demand and accelerate the growth in our US operations as we progress towards our commercialisation and medical device registration milestones.”

New shares from the SPP – which is not underwritten and is capped at $2m – will be issued at the offer price of A$2.60, and will rank equally with existing Vitrafy shares as at their date of issue.